ArticleNature medicine2017
The small molecule CLP257 does not modify activity of the K
Open access · greenAbstract readLetter
In one paragraph
Article in Nature medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 49 citations in OpenAlex.
- Regulated degradation of KCC2, a potassium-chloride co-transporter required for synaptic transmission and neurodevelopment.Channels (Austin, Tex.) · 2026Review
- Enhancing KCC2 function reduces interictal activity and prevents seizures in temporal lobe epilepsy.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Article
- New epilepsy therapies in development.Nature reviews. Drug discovery · 2024Review
- Combined use of CLP290 and bumetanide alleviates neuropathic pain and its mechanism after spinal cord injury in rats.CNS neuroscience & therapeutics · 2024Article
- Compound 350: A New Hope for Individuals with Drug-resistant Epilepsy.Annals of neurosciences · 2024Article
- Neuronal KActa pharmacologica Sinica · 2024Review
- Serine 937 phosphorylation enhances KCC2 activity and strengthens synaptic inhibition.Scientific reports · 2023Article
- The role ofJournal of pharmaceutical analysis · 2023Review
- KCC2 reverse mode helps to clear postsynaptically released potassium at glutamatergic synapses.Cell reports · 2023Article
- Direct activation of KCC2 arrests benzodiazepine refractory status epilepticus and limits the subsequent neuronal injury in mice.Cell reports. Medicine · 2023Article
- Review
- Structural Pharmacology of Cation-Chloride Cotransporters.Membranes · 2022Review
- Molecular Mechanisms of Epilepsy: The Role of the Chloride Transporter KCC2.Journal of molecular neuroscience : MN · 2022Review
- Inhibiting with-no-lysine kinases enhances K+/Cl- cotransporter 2 activity and limits status epilepticus.Brain : a journal of neurology · 2022Article
- Discovery of Small Molecule KCC2 Potentiators Which AttenuateFrontiers in cell and developmental biology · 2022Article
- Targeting ischemia-induced KCC2 hypofunction rescues refractory neonatal seizures and mitigates epileptogenesis in a mouse model.Science signaling · 2021Article
- Protein post-translational modifications after spinal cord injury.Neural regeneration research · 2021Review
- The role of GABAergic signalling in neurodevelopmental disorders.Nature reviews. Neuroscience · 2021Review
- Enhancing KCC2 activity decreases hyperreflexia and spasticity after chronic spinal cord injury.Experimental neurology · 2021Article
Corrections and comments
- Commented on by
Authors and funding
24 authors at 5 institutions in 4 countries.
Ross A CardarelliAstraZeneca Tufts Laboratory for Basic and Translational Neuroscience, Boston, Massachusetts, USA.ORCID 0000-0002-3692-6708
Karen JonesDiscovery Sciences, IMED Biotech Unit, AstraZeneca, Alderley Park, UK.
Lucie I PisellaINMED, INSERM, Unité 901, Marseille, France.
Heike J WobstAstraZeneca Tufts Laboratory for Basic and Translational Neuroscience, Boston, Massachusetts, USA.
Lisa J McWilliamsDiscovery Sciences, IMED Biotech Unit, AstraZeneca, Cambridge, UK.
Paul M SharpeDiscovery Sciences, IMED Biotech Unit, AstraZeneca, Alderley Park, UK.ORCID 0000-0003-2116-9561
Matthew P BurnhamDiscovery Sciences, IMED Biotech Unit, AstraZeneca, Alderley Park, UK.
David J BakerDiscovery Sciences, IMED Biotech Unit, AstraZeneca, Cambridge, UK.
Ilona ChudotvorovaINMED, INSERM, Unité 901, Marseille, France.
Justine GuyotINMED, INSERM, Unité 901, Marseille, France.
Liliya SilayevaAstraZeneca Tufts Laboratory for Basic and Translational Neuroscience, Boston, Massachusetts, USA.
Danielle H MorrowDepartment of Neuroscience, Tufts University School of Medicine, Boston, Massachusetts, USA.
Niek DekkerDiscovery Sciences, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
Stephen ZichaNeuroscience, IMED Biotech Unit, AstraZeneca, Boston, Massachusetts, USA.
Paul A DaviesDepartment of Neuroscience, Tufts University School of Medicine, Boston, Massachusetts, USA.
Jörg HolenzNeuroscience, IMED Biotech Unit, AstraZeneca, Boston, Massachusetts, USA.
Mark E DugganNeuroscience, IMED Biotech Unit, AstraZeneca, Boston, Massachusetts, USA.
John DunlopNeuroscience, IMED Biotech Unit, AstraZeneca, Boston, Massachusetts, USA.
Robert J MatherNeuroscience, IMED Biotech Unit, AstraZeneca, Boston, Massachusetts, USA.
Qi WangAstraZeneca Tufts Laboratory for Basic and Translational Neuroscience, Boston, Massachusetts, USA.
Igor MedinaINMED, INSERM, Unité 901, Marseille, France.
Nicholas J BrandonAstraZeneca Tufts Laboratory for Basic and Translational Neuroscience, Boston, Massachusetts, USA.
Tarek Z DeebAstraZeneca Tufts Laboratory for Basic and Translational Neuroscience, Boston, Massachusetts, USA.
Stephen J MossAstraZeneca Tufts Laboratory for Basic and Translational Neuroscience, Boston, Massachusetts, USA.
Tufts University · USAstraZeneca (United Kingdom) · GBAstraZeneca (United States) · USInserm · FRAstraZeneca (Sweden) · SE
Funding
Mechanisms that determine Glutamine synthetase activity in the brainR01NS081986 · NINDS · TUFTS UNIVERSITY BOSTON · PI MOSS, STEPHEN J · 2012 to 2022
$3.7MConstructing inhibitory synapsesR01NS051195 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI MOSS, STEPHEN J · 2006 to 2014
$3.2MModulation of KCC2 activity and the postnatal development of synaptic inhibitionR01NS101888 · NINDS · TUFTS UNIVERSITY BOSTON · PI DEEB, TAREK ZIAD, MOSS, STEPHEN J · 2017 to 2021
$2.3MNovel actions of neurosteroids on GABA (A) receptor traffickingR01MH097446 · NIMH · TUFTS UNIVERSITY BOSTON · PI DAVIES, PAUL ANDREW, MOSS, STEPHEN J · 2013 to 2017
$2.1MNovel actions of neurosteroids on GABA (A) receptor traffickingR01NS108378 · NINDS · TUFTS UNIVERSITY BOSTON · PI DAVIES, PAUL ANDREW, MOSS, STEPHEN J · 2018 to 2022
$2.0MDeficits in KCC2 activity and the pathophysiology of Status EpilepticusR01NS087662 · NINDS · TUFTS UNIVERSITY BOSTON · PI MOSS, STEPHEN J · 2014 to 2018
$2.0MThe role of ubiquitination in regulating GABA(A) receptor functional expressionR01NS056359 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI MOSS, STEPHEN J · 2007 to 2010
$1.4MMechanisms that determine the activity of glutamine synthetase in the brainR21NS103865 · NINDS · TUFTS UNIVERSITY BOSTON · PI MOSS, STEPHEN J · 2018 to 2019
$454kImpaired KCC2 function underlies pharmacoresistant seizuresR21NS080064 · NINDS · TUFTS UNIVERSITY BOSTON · PI MOSS, STEPHEN J · 2013 to 2014
$452kNIH HHS MH097446NIH HHS NS051195NIH HHS NS056359NIH HHS NS081735NIH HHS NS087662NIMH NIH HHS R01 MH097446NINDS NIH HHS R01 NS051195NINDS NIH HHS R01 NS056359NINDS NIH HHS R01 NS081986NINDS NIH HHS R01 NS087662NINDS NIH HHS R01 NS101888NINDS NIH HHS R01 NS108378NINDS NIH HHS R21 NS080064NINDS NIH HHS R21 NS103865
Abstract
PubMed holds no abstract for this paper.
Indexed as
Cell Line, TumorChloridesHEK293 CellsHumansK Cl- CotransportersPatch-Clamp TechniquesProtein BindingReceptors, GABA-ASymportersThalliumThiazolidinesTransfectionChloridesCLP257K Cl- CotransportersReceptors, GABA-ASymportersThalliumThiazolidines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.